title: Cancer Precision Medicine: From Cancer Screening to Drug Selection and Personalized Immunotherapy.
abstract: With the accelerating progress in basic and clinical cancer research, a huge body of new discoveries and powerful technologies has allowed us to implement a 'Cancer Precision Medicine (CPM)' system for cancer patients. The CPM system covers a wide range of cancer management including cancer screening, monitoring of relapse/recurrence, selection/prediction of effective drugs/treatments, and personalized immunotherapy. In this system individual cancer patients expect to receive personalized care: an appropriate dose of the right drug at the right time. We here aim to summarize and discuss a possible workflow for precision medicine for cancer patients by reviewing recent booming technologies and treatments that have been used or will potentially be used in the CPM system.
authors.affiliation: Section of Hematology/Oncology, Department of Medicine, The University of Chicago, 5841 S. Maryland Avenue, MC2115 Chicago, IL 60637, USA.
authors.forename: Xiaolan
authors.initials: X
authors.lastname: Deng
authors.affiliation: Section of Hematology/Oncology, Department of Medicine, The University of Chicago, 5841 S. Maryland Avenue, MC2115 Chicago, IL 60637, USA. Electronic address: ynakamura@bsd.uchicago.edu.
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Nakamura
mesh_terms: D004273:DNA, Neoplasm / Q000097:blood; D055088:Early Detection of Cancer; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D007167:Immunotherapy; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis; D009369:Neoplasms / Q000628:therapy*; D010597:Pharmacogenetics; D057285:Precision Medicine; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics; D017422:Sequence Analysis, DNA
chemical_list: D004273:DNA, Neoplasm; C117307:KRAS protein, human; D066246:ErbB Receptors; D016283:Proto-Oncogene Proteins p21(ras)
keywords: HLA; TCR-engineered T cells; immunopharmacogenomics; liquid biopsy; neoantigen and shared-antigen vaccine; personalized immunotherapy